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Diagnosis of Transmissible 
Spongiform Encephalopathy (TSE) disease 
in humans and ruminants relies on the 
detection in post mortem brain tissue of the 
protease resistant form of the host 
glycoprotein PrP.  Presence of this 
abnormal isoform (PrPSc) in tissues is taken 
as indicative of the presence of TSE 
infectivity.  Here we demonstrate 
conclusively that high titres of TSE 
infectivity can be present in brain tissue of 
animals which show clinical and vacuolar 
signs of TSE disease, but contain low or 
undetectable levels of PrPSc. This work 
questions the correlation between PrPSc 
level and the titre of infectivity, and shows 
that tissues containing little or no PK 
resistant PrP can be infectious and harbour 
high titres of TSE infectivity. Reliance on 
protease resistant PrPSc as a sole measure 
of infectivity may therefore in some 
instances significantly underestimate 
biological properties of diagnostic samples, 
thereby undermining efforts to contain and 
eradicate TSEs. 
The transmissible spongiform 
encephalopathy (TSE) diseases (also known as 
prion diseases) are infectious, fatal 
neurodegenerative diseases of animals, which 
include Creutzfeldt Jacob disease (CJD) in 
humans and bovine spongiform 
encephalopathy (BSE) in cattle.  The true 
identity of the infectious agent responsible for 
these diseases is not known. However, it has 
been proposed that TSE disease is caused by 
an abnormal form of the host glycoprotein, 
PrP (1).  The abnormal, disease associated 
form of the protein (PrPSc), is partially 
protease resistant and detergent insoluble 
unlike the normal cellular conformer (PrPC), 
and is seen to accumulate in diseased tissues.  
The prion hypothesis predicts that PrPSc alone 
is the infectious agent of TSE, and is able to 
induce the conversion of endogenous PrPC 
into the abnormal form during disease (2). 
Most human TSE diseases are familial 
or sporadic, but disease can also be acquired 
by surgical intervention (3) or blood 
transfusion from infected individuals (4-9), or 
possibly from the consumption of BSE 
infected meat products, the presumed cause of 
variant CJD (vCJD) (10).  The extent to which 
vCJD infection in particular is present in the 
UK population is unknown, but recent 
research has suggested there may be a higher 
rate of sub-clinical or pre-clinical vCJD than 
previously thought in different human PrP 
genotypes (7,11-13). Although BSE is 
declining in the UK, cases have now been 
observed in cattle in countries that have not 
previously reported BSE. It is also unknown 
whether the agent responsible for BSE has re-
entered the human food chain following 
transmission to sheep.  For these reasons a 
high level of active and passive surveillance of 
ruminants is required at slaughter to monitor 
and prevent TSE infected material from 
entering the human food chain.  The 
introduction of ante-mortem surveillance in 
the human population is also critical to 
prevent the human-to-human transmission of 
vCJD by blood transfusion or surgical 
procedures.  This will be of particular 
importance if subclinical disease proves to be 
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a significant risk in vCJD transmission 
(12,13). 
Positive identification of TSE 
infectivity can only be demonstrated 
conclusively by transmission of disease to 
laboratory animals.  Such assays are time 
consuming, due to long incubation times, and 
expensive, and are therefore not suitable for 
the rapid diagnosis of all ante- or post-mortem 
samples.  Current diagnostic tests instead rely 
on the detection of disease associated PrPSc in 
samples taken from brain post-mortem.  The 
development of ante-mortem diagnostic tests 
is also being based around more sensitive 
assays for PrPSc. Several diagnostic tests are 
available commercially, and most require 
proteinase K (PK) treatment of tissue 
homogenates to isolate disease specific PK 
resistant PrPSc (PrP-res).  It has not yet been 
definitively proven that PrPSc is the TSE 
infectious agent, and whether it is present in 
all infected tissues.  Studies using 263K 
hamster scrapie have shown a strong 
correlation between PrP-res and infectivity 
(2,14,15).  However other studies have 
demonstrated the transmission of disease from 
infected animals which appear to lack 
significant levels of PrP-res (16-19).  In such 
cases it has been suggested that a PK-sensitive 
form of PrPSc (sPrPSc) may represent the 
infectious agent (20-22). Hence it is possible 
that infectivity may be associated with a 
specific isoform of abnormal PrP. The 
identification of this specific conformer is 
imperative for the future of TSE diagnosis. 
However, if TSE infectivity does not always 
associate with high levels of PrPSc, current 
diagnostic methods may fail to identify all 
animals with TSE disease, and may not 
provide a realistic estimate of the level of 
infectivity in an infected tissue. For the 
purposes of this study, PrPSc is used to define 
all abnormal forms of PrP, whereas PrP-res 
specifically defines PK-resistant PrP, and 
sPrPSc defines PK-sensitive forms of PrPSc.  If 
present, large amounts of PrPSc may be a clear 
indication of the presence of infectivity in a 
tissue sample.   
 We have previously identified two 
mouse models of TSE disease (18,19) which 
indicate that the association between PrP-res 
and infectivity is not as straightforward as 
predicted by the prion hypothesis.  Unlike 
wild-type controls, transgenic mice 
homozygous for a targeted mutation at amino 
acid 101 (proline to leucine) in endogenous 
murine PrP (101LL) develop clinical TSE 
disease following inoculation with hamster 
263K scrapie or human Gerstmann Sträussler 
Scheinker (GSS) P102L disease (patient 
shown to contain vacuolar pathology and PrP-
res at post mortem) (18,19). Pathological 
analysis of brain tissue from these mice 
(101LL/GSS and 101LL/263K) showed TSE 
associated vacuolation, and the disease could 
be further transmitted to 101LL mice with 
short incubation times of 100-160 days 
(18,19). Such incubation times were indicative 
of a high titre of infectivity in the 101LL/GSS 
and 101LL/263K tissues, yet analysis by 
immunoblot revealed that most animals 
contained extremely low levels of PrP-res, and 
several contained no detectable PrP-res at all 
(18,19). However, the presence of high titres 
of infectivity cannot be proven by a short 
disease incubation time. In order to establish 
the true relationship between PrPSc and 
infectivity we have now performed more 
detailed and quantitative analyses of the 
disease in these mice. The ID50 (dilution at 
which 50% of the animals become infected) 
and titre of infectivity in several 101LL/GSS 
and 101LL/263K infected brains have been 
established by bioassay. Corresponding levels 
of PrP-res in the same tissues have also been 
established semi-quantitatively by 
immunoblot. These analyses have shown no 
relationship between infectivity titre and PrP-
res level. Moreover no other disease-
associated forms of PrP were detectable in 
these tissues. Thus within our model system 
there is a clear dissociation between titre of 
infectivity and level of PrPSc. 
 
Experimental procedures. 
 
Transgenic mouse lines and tissues - Inbred 
gene targeted transgenic mouse line 101LL, 
and the corresponding inbred 129/Ola wild 
type control line have been described 
previously (18).   101LL/GSS tissues were 
 2
produced by inoculation of 101LL transgenic 
mice with 1% brain homogenate prepared 
from the occipital cortex of a GSS P102L 
brain showing numerous multicentric plaques 
and abundant PrP-res by immunoblot.  The 
individual was 129 methionine homozygous 
with a confirmed proline to leucine mutation 
at codon 102 (J. W. Ironside and M. W. Head, 
personal communication).  101LL/263K 
tissues were produced by inoculation of 
101LL transgenic mice with 1% brain 
homogenate from a 263K infected hamster.  
Control tissues were produced by ME7 
inoculation of 129/Ola wild type mice and 
101LL transgenic mice. 
Preparation of inocula - Separate inocula 
were prepared from the brains of two 
101LL/GSS and three 101LL/263K infected 
mice with terminal TSE disease which had 
been shown by immunohistochemical (IHC) 
analysis to contain extremely low levels of 
PrP deposition. Inocula were also prepared 
from brains of one wild type and one 101LL 
mouse with terminal ME7 scrapie as controls.  
A 10% homogenate of each sample was 
prepared in sterile saline prior to use as an 
inoculum. This inoculum was then used to 
produce a series of 10-fold dilutions from 10-2 
to 10-9 in sterile saline.  Each dilution (20μl) 
was inoculated intracerebrally under 
anaesthesia into groups of 101LL mice for 
101LL/ME7, 101LL/GSS and 101LL/263K 
tissues, or wild type 129/Ola mice for 
101PP/ME7 tissue. All experimental protocols 
were submitted to the Local Ethical Review 
Committee for approval before mice were 
inoculated.  All experiments were performed 
under licence and in accordance with the UK 
Home Office Regulations (Animals (Scientific 
Procedures) Act 1986). 
Scoring of clinical TSE disease - The presence 
of clinical TSE disease was assessed as 
described previously (23). Animals were 
scored for clinical disease without reference to 
the genotype of the mouse.  Genotypes were 
confirmed for each animal by PCR analysis of 
tail DNA at the end of the experiment. 
Incubation times were calculated as the 
interval between inoculation and cull due to 
terminal TSE disease. Mice were killed by 
cervical dislocation at the terminal stage of 
disease, at termination of the experiment 
(between 500-700 days), or for welfare 
reasons due to intercurrent illness.  The 
proportion of mice showing positive vacuolar 
pathology was calculated for each group, and 
the ID50 (dilution at which 50% of the mice 
became infected) was determined using the 
Karber method (24).  This value was used to 
calculate the number of infectious units per 
gram wet weight of tissue (IU/g). 
Genotyping of mouse-tail DNA - A 2-3cm 
portion of tail was removed post-mortem from 
each mouse. DNA was prepared and the PrP 
genotype of each mouse confirmed as 
described previously (18).   
Immunoblot analysis and quantification of 
PrP-res - For immunoblot analysis, residual 
inocula (10% saline homogenate) were mixed 
with an equal volume of 2x NP40 buffer [2% 
NP40, 1% sodium deoxycholate, 300mM 
NaCl, 100mM Tris/HCl pH7.5]  and further 
homogenised in a microcentrifuge tube using 
20-30 strokes with a pre-cooled centrifuge 
tube pestle (Anachem).  The homogenate was 
centrifuged at 11,000g for 10min at 100C to 
remove cellular debris, and the supernatant 
stored in 50µl aliquots at -700C.  For 
quantification of PrP-res levels in each tissue, 
homogenates were digested with 20µg/ml 
proteinase K (PK) at 370C for 1h.  Digested 
homogenates were diluted to 1%, and two-fold 
serial dilutions were prepared using PK 
treated normal brain homogenate as the 
diluent to keep overall protein concentrations 
constant.  Diluted samples were mixed with 
sample loading buffer and sample reducing 
agent (Invitrogen) and loaded across two 12% 
tris/glycine polyacrylamide gels (Invitrogen) 
at concentrations ranging from 1mg/ml to 
3.9µg/ml  (200µg to 0.8µg wet weight tissue 
equivalent).  50ng of recombinant PrP was 
loaded onto each gel as an internal control.  
After separation, proteins were transferred 
onto PVDF membrane by electroblotting and 
PrP was detected with monoclonal antibody 
8H4 (West Dura ECL substrate; Pierce).   
Monoclonal antibody 7A12 and polyclonal 
antibody 1B3 were also used to confirm the 
low PrP-res levels in 101LL/GSS and 
101LL/263K tissues.  Images were captured 
on both X-ray film and by a Kodak Digital 
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Image Station 440.  Experiments were 
repeated in duplicate or triplicate depending 
on sample availability.   
Digital images of each gel were analysed 
using Kodak ID software, and PrP-res levels 
expressed as pixel intensities.  Samples were 
normalised across the two blots and quantified 
using the recombinant PrP controls as 
standards.  Each value was multiplied by the 
dilution factor and an average was taken for 
all samples run per tissue to determine the 
level of PrP-res per gram wet weight brain 
tissue in each model.  This value, combined 
with the titre of TSE infectivity measured in 
each tissue (IU/g) was used to calculate the 
number of molecules of PrP-res per infectious 
unit for each tissue as follows;   
Number PrP-res Molecules per gram of tissue 
= n 
n = [PrP-res per gram (g) / Avagadro’s 
number (6.02 x 1023)] / Mwt PrP (30,000) 
Number of molecules PrP-res per infectious 
Unit = n / titre (IU/g) 
Measurement of alternative forms of PrP - 
The proteinase K (PK) resistance of PrP in all 
samples was analysed by digestion with a 
range of PK concentrations.  Individual 9µl 
aliquots of each 5% NP40 brain homogenate 
were incubated at 370C for 1h with PK 
concentrations ranging from 1µg/ml to 
20µg/ml.  The reaction was terminated by 
addition of Phenylmethylsulphonyl fluoride 
(PMSF) to 1mM, and samples were analysed 
by SDS PAGE and immunoblotting as 
described above.   
For “cold PK” digestion, samples (10% 
homogenate) were incubated with 250µg/ml 
PK on ice for 1h.  Digestion was stopped by 
the addition of PMSF to 1mM.  Samples were 
de-glycosylated with PNGase F (New England 
Biolabs) following the manufacturers 
instructions, and analysed by SDS PAGE and 
immunoblotting. 
DELFIA analysis - Dissociation Enhanced 
Lanthanide Fluoro Immuno Assay (DELFIA) 
analysis of brain homogenate was performed 
using a modification of the method described 
by Barnard et al. (25).  Briefly, 50µl of 10% 
PBS brain homogenate was mixed with an 
equal volume of 2M GdnHCl and 
homogenised in a microfuge tube with a 
microfuge pestle (Anachem).  Samples were 
re-homogenised after addition of 50µl of 1x 
NP40 buffer, vortexed for 2 min and mixed 
with 850µl of assay buffer (Perkin Elmer).  
Samples were centrifuged at 13,000g for 10 
min to produce Supernatant 1 (1M GdnHCl 
soluble fraction).  Pellets were re-suspended in 
100µl of 6M GdnHCl, mixed with 900µl of 
assay buffer and spun at 13,000g for 10 min to 
produce Supernatant 2 (1M GdnHCl insoluble 
fraction). 1M GdnHCl soluble and insoluble 
fractions were added to 96 well plates pre-
coated with MAb FH11, and PrP levels in 
each fraction were detected with Europium 
labelled MAb 7A12 according to the 
manufacturers’ instructions (Perkin Elmer).  
Recombinant PrP standards were included in 
each assay for calibration.  Samples were 
assayed in duplicate, and the percentage 
coefficient of variation calculated for each 
sample pair. 
Immunoprecipitation of PrP PSc. 
Laterally bisected brain halves from 101LL 
transgenic mice were homogenised at 10% 
(w/v) in Tris-buffered saline (TBS) and 
diluted to reach a concentration of 5% (w/v) in 
TBS containing 1% Triton. Homogenates 
were sonicated for three pulses of 4 seconds 
and clarified by centrifugation at 400g for 10 
min at 4oC. PMSF was added to all samples to 
a concentration of 2mM. Each sample was 
analysed by dot blot to estimate the total PrP 
content.  Briefly, brain homogenates were 
serially diluted (1:1) in TBS containing 1% 
Triton then denatured in Tris-SDS sample 
buffer at 100oC for 5 min.  Equivalent 
amounts of each sample were then deposited 
on a nitrocellulose membrane and left until 
dry.  The membrane was probed with Mab 
6H4 (Prionics) and an HRP labelled anti-
mouse secondary antibody (Pierce).  The 
resulting signals were compared semi-
quantitatively.  These data were used to ensure 
equal PrP input into each individual 
immunoprecipitation (IP) reaction. For each 
IP reaction, the motif grafted antibodies or 
control antibodies were incubated at 10μg/ml 
final concentration for 2h at RT in a reaction 
mixture including 1% Triton.  Rabbit anti-
human antibodies (Jackson) coupled to 
magnetic dynabeads (Dynal) were used to 
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capture the PrP-specific antibodies as 
described (26,27). Immunoblot membranes 
were probed with Mab 6H4 and developed 
using the ECL femtomolar kit (Pierce). 
 
RESULTS. 
 
101LL mice infected with 263K and 
GSS P102L show little PrP deposition in 
brain; Brain tissue from 101LL transgenic 
mice which showed TSE clinical signs and 
TSE associated vacuolar pathology following 
inoculation with hamster 263K scrapie or 
human GSS P102L (18,19) was screened for 
PrP deposition by immuno-histochemistry 
(IHC) using anti-PrP monoclonal antibody 
6H4. As previously demonstrated, 
101LL/GSS and 101LL/263K infected mice 
had low levels of PrP deposition in the brain, 
despite having confirmed TSE disease. Three 
101LL/263K and two 101LL/GSS infected 
tissues, which showed extremely low PrP 
deposition in the brain, were selected for 
further analysis by bioassay (Figure 1 and 
Table 1).  In each case, PrP deposition was 
restricted to the thalamus, and in most cases 
was only visible as small grainy deposits 
under high power microscopy (Figure 1G-I). 
Low or undetectable levels of PrP-res in each 
brain homogenate were confirmed by 
immunoblot following PK treatment of 
residual inoculum (Figure 2). 
High levels of infectivity can be 
measured by bio-assay of 101LL/GSS and 
101LL/263K brain tissue. Although short 
incubation times in mice can be indicative of 
high levels of TSE infectivity in an inoculum, 
the actual level can only be determined by 
establishing the ID50 (dilution at which 50% of 
the animals become infected) for the 
inoculum.  Infectivity titres were therefore 
established for the five selected tissues; 
101LL/263K(a), 101LL/263K(b), 
101LL/263K(c), 101LL/GSS(d) and 
101LL/GSS(e) (Table 1). It was considered 
extremely important in these experiments that, 
as far as possible, a single brain be used for 
each series of procedures (ID50 determination, 
PK digestion, IHC, etc..). This allowed direct 
correlation to be made between the level of 
infectivity and PrP-res in each individual brain 
and avoided any variation which may occur 
between tissues, as is often observed on a 
primary transmission. Moreover this approach 
avoided the necessity of carrying out large 
numbers of titration experiments which would 
have been both impractical and ethically 
unacceptable. Inocula were prepared from 
each individual tissue as 10% sterile saline 
homogenates, and used to produce a series of 
10-fold dilutions (10-2 to 10-9) for inoculation. 
Wild type control 129/Ola and transgenic 
101LL mouse brains infected with the well 
characterised mouse scrapie strain ME7 
(Wt/ME7 and 101LL/ME7 respectively) (18) 
were also assayed as controls. The seven 
samples were inoculated intracerebrally (i.c.) 
into groups of 129/Ola mice for Wt/ME7, and 
transgenic 101LL mice for all other samples.  
The percentage of mice which developed TSE 
pathology was calculated for each group in 
each dilution series, and the ID50 was 
determined using the Karber calculation  (24).   
The number of infectious units per gram tissue 
(IU/g) for each individual mouse brain are 
shown in Table 2. Assuming a ± 0.5 log error 
for each titre (24), all 101LL/GSS and 
101LL/263K samples produced titres of 
infectivity ranging from ~107 to 109 IU/g. The 
highest titre (109.8) was identified in 
101LL/GSS(d), however a titre of 108.7 was 
also identified in 101LL/263K(a). Both of 
these brains showed low levels of PrP 
deposition by IHC, but titres were higher than 
that measured in control Wt/ME7 brain (108.5) 
which showed significantly more PrP 
deposition by IHC (Figure 1). Titres in the 
other three tissues were similar (107.2 to 107.5) 
and confirmed a high level of infectivity in the 
presence of extremely low or undetectable PrP 
deposition in the brain (Figure 1 and 2). The 
results of the ID50 determination therefore 
prove the presence of high levels of infectivity 
in 101LL transgenic mice infected with P102L 
GSS or hamster 263K.   
 Little or no PrP-res is detected in 
highly infectious tissue. IHC using anti-PrP 
monoclonal and polyclonal antibodies found 
little or no PrP deposition in brain tissue of 
101LL/263K and 101LL/GSS infected mice 
(Figure 1, and data not shown). However, IHC 
does not distinguish between different forms 
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of PrP, therefore direct measurement of brain 
PrP-res levels was undertaken to determine 
the amount of PrP-res associated with titre of 
infectivity in each brain, listed in Table 1. 
Residual inoculum from each bioassay was 
mixed with detergent buffer, digested with PK 
(Figure 2) and a 2-fold serial dilution from 
1mg/ml to 3.9µg/ml (wet weight brain tissue) 
analysed by immunoblotting with monoclonal 
antibody 8H4 (28).  Recombinant PrP (rec-
PrP) was loaded on each gel at 50ng as an 
internal control.  For the ME7 infected tissues, 
the limit of PrP-res detection was 15.6µg/ml 
for Wt/ME7 homogenate, and 31.3µg/ml for 
101LL/ME7 homogenate.  Hence the same 
agent produced approximately 2-fold less PrP-
res in the 101LL transgenic mice compared to 
wild type mice, although this was associated 
with a 0.7 log drop in titre (Table 2).  In 
101LL/263K(a) the limit of PrP-res detection 
was 62.5µg/ml brain homogenate, which was 
approximately half the level in 101LL/ME7 
and one quarter the level in Wt/ME7.  For all 
other samples, no PrP-res was detectable in 
even the most concentrated (1mg/ml) sample 
examined (Table 2, Figure 2, Supplemental 
Figure 1A).  Digital imaging of immunoblots 
and quantitation of PrP-res relative to 
recombinant PrP control, allowed the 
calculation of PrPSc concentration (mean PrP-
res gram per gram wet weight of tissue) in 
each sample (Table 2).  The level of 
sensitivity for the immunoblot, determined 
using recombinant PrP, was 5-10ng, therefore 
the level of PrP-res in samples which showed 
no PK-resistant material must be below this 
threshold.  Previous studies have shown that 
PrP-res from other well characterised rodent 
scrapie strains with titres ranging from 105.5 to 
109 can be easily identified on immunoblot of 
1% brain homogenate following PK treatment 
(Supplemental Figure 1B). These data would 
suggest that tissue containing titres of 107 to 
109 IU/g should contain levels of PrP-res 
which can be easily identified by immunoblot. 
However for 101LL/GSS and 101LL/263K 
infected tissue this is clearly not the case. 
While we cannot eliminate the possibility that 
PrP-res was indeed present below the 
threshold level of the immunoblot, a poor 
correlation between the level of infectivity and 
the amount of PrP-res in the brain is 
nevertheless clearly established.  In order to 
confirm that the failure to detect PrP-res on 
these immunoblots was not simply a 
consequence of the loss of the monoclonal 
antibody epitope (8H4) duplicate blots were 
also probed with a second monoclonal 
antibody (7A12) and a polyclonal antibody 
(1B3) which detects multiple epitopes in PrP. 
These results confirmed the low PrP-res levels 
in 101LL/GSS and 101LL/263K tissues (data 
not shown). While the combination of 
monoclonal and polyclonal antibodies used to 
examine these tissues make it unlikely that a 
form of PrP-res exists which has not been 
detected in our immuno-assays, this 
possibility has not been totally excluded and 
we continue to investigate these tissues with 
new antibodies. 
 Are alternative forms of PrP 
associated with infectivity? Although PrP-res 
was present at low or undetectable levels in 
tissues from 101LL/GSS and 101LL/263K 
infected mice, it is possible that forms of PrP 
other than PrP-res may be infectious (29).  
Alternative forms of PrP such as 
transmembrane PrP (30,31) cytoplasmic PrP 
(32,33), and PrP with amino acid insertions or 
deletions (34-37) have been linked with 
disease.  In addition, a PK-sensitive variant of 
PrPSc (sPrPSc), has been recently described 
(20-22), which may represent an intermediate 
in the refolding of PrPC to PrPSc during the 
disease process, and could therefore be 
associated with infectivity.  In order to test 
whether sPrPSc may account for the 
dissociation between PrP-res and infectivity in 
101LL/263K and 101LL/GSS tissues we 
examined the protease resistance of PrP in 
such brains by digesting with a range of PK 
concentrations from 1µg/ml to 20µg/ml.  
Homogenates from Wt/ME7, 101LL/ME7 and 
uninfected 101LL and 129/Ola mice were also 
treated with varying PK concentrations as 
controls.  Digestion was stopped by the 
addition of PMSF to 1mM, and samples were 
analysed by immunoblot (Figure 3).  In the 
positive controls (Wt/ME7 and 101LL/ME7) 
PrP-res was evident in all dilutions, with the 
PK-resistant core still visible after treatment 
with 20µg/ml PK (data not shown).  PrP in the 
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uninfected controls was found to be sensitive 
to PK concentrations greater than 5µg/ml, and 
produced mildly PK-resistant fragments at PK 
concentrations of 2-5µg/ml under the 
digestion conditions used here (Figure 3). PrP 
in the 263K infected 101LL brains showed 
variable PK resistance, in agreement with the 
level of PrP-res detectable in each 
homogenate. Thus, 101LL/263K(a) showed 
PrP-res at 20µg/ml, but 101LL/263K(b) & (c) 
showed a similar pattern of PK-resistance to 
uninfected mice.  In addition, samples from 
both 101LL/GSS(d) (Figure 3) and 
101LL/GSS(e) showed a PK sensitivity 
pattern identical to that of uninfected 101LL 
mice.   
 The presence of sPrPSc in brain tissue 
has also been demonstrated by performing 
“cold PK digestion”, i.e. PK digestion on ice 
(21,22). sPrPSc has been previously identified 
in samples which showed no PrP-res (using 
standard digestion conditions of 20µg/ml for 
1h at 370C) by the presence of a 22kDa band 
on immunoblot after digestion with PK on ice 
and subsequent de-glycosylation with PNGase 
F (21,22).  Although we aimed to perform all 
procedures on each individual mouse brain, 
the limited tissue size meant this was not 
possible for the “cold PK” analyses carried out 
here. However “cold PK” digestion was 
performed on brain tissue taken from mice 
showing positive clinical and vacuolar signs 
of TSE, but low levels of PrP deposition in the 
same primary transmission experiments as 
those listed in Table 2 (details in Figure S2 
and Table S1). These tissues failed to 
demonstrate any marked increase in the 
22kDa PK-resistant PrP band after “cold PK” 
digestion (Figure 4, lanes 2 and 3).  When 
compared to the ME7 control (Figure 4 lane 6, 
loaded at 25% concentration of lanes 2-5), the 
low levels of PrP apparent in lanes 2 and 3 
after digestion with PK on ice demonstrate 
that sPrPSc cannot account for the high titre of 
infectivity in the 101LL/263K and 
101LL/GSS models.   
 Although PrP PSc is generally defined by 
its partial resistance to PK digestion, it can 
also be identified by its differential solubility 
in guanidine hydrochloride (Gdn-HCl).  While 
PrPC is soluble in 1M Gdn-HCl, PrPSc is not, 
and the two forms can therefore be separated 
by centrifugation of brain homogenate in 1M 
Gdn-HCl.  Resulting pellets can be solubilised 
in 6M Gdn-HCl and the two fractions (1M and 
6M) assayed for PrP content by DELFIA 
sandwich ELISA (25).  Samples from 
101LL/GSS(d) and 101LL/GSS(e) infected 
mice which contained no PrP-res by 
immunoblot but showed titres of 109.8 and 
107.2 IU/g by bioassay were subjected to this 
analysis.  PrP levels detected in the 1M Gdn-
HCl insoluble fraction by DELFIA were 
similar to those in uninfected mice (Figure 5), 
indicating that no PrPSc-like conformers were 
present in these tissues.  Levels of PrP 
detected in the 1M soluble fraction were 
variable, but fell within the range observed for 
control (uninfected) 101LL mice, indicating 
that PrP levels in brain tissue harbouring titres 
of 107.2-109.8 IU/g could not be differentiated 
by PrP-specific DELFIA from those in 
uninfected control 101LL mouse tissue.  
101LL/263K samples which had been titrated 
by bioassay were not analysed by DELFIA 
due to limited sample availability.  However 
one further brain from the same 263K 
transmission experiment which showed 
clinical and vacuolar signs of TSE but did not 
contain PrP-res by immunoblot was analysed 
and found to contain no 1M Gdn-HCl 
insoluble material (Figure 5).  
 Immunoprecipitation using PrPSc 
specific monoclonal antibodies. Several 
monoclonal antibodies (MAbs) have been 
generated which specifically bind PrPSc 
isoforms, but not PrPC. These antibodies can 
therefore isolate PrPSc from non-PK treated 
tissue homogenates by immunoprecipitation, 
ensuring that all abnormal PrP isoforms are 
identified. This technique has been used by 
others to demonstrate the presence of sPrPSc in 
the brains of mice overexpressing 101L-PrP 
(22). Here, PrPSc-specific motif grafted MAbs 
89-112 and 136-158 (26) were used to 
immunoprecipitate PrP from brain tissue 
homogenates of 101LL/GSS and 101LL/263K 
infected mice. Tissues analysed were taken 
from mice showing positive clinical and 
vacuolar signs of TSE, but low levels of PrP 
deposition in the same primary transmission 
experiments as those used to determine titre of 
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infectivity in each model (details in Figure S2 
and Table S1).  Positive control MAb D13 
(which precipitates only the cellular form of 
PrP) and negative control MAb b12 were also 
included in all experiments. For all 
101LL/GSS and 101LL/263K tissues 
examined, extremely low levels of PrPSc were 
immunoprecipited by both PrPSc-specific 
antibodies (Figure 6). These levels were 
estimated by immunoblot to be 100-1000 fold 
less than those precipitated from control RML 
infected mouse brain. Results from these 
immunoprecipitations therefore support our 
previous biochemical data which show no 
evidence of PK-sensitive forms of PrPSc in 
brain tissue from 101LL/GSS and 
101LL/263K infected mice.  
 
DISCUSSION. 
 
 PrPSc is thought to be the sole 
component of the prion, or TSE infectious 
agent. For this reason it has become the main 
target for TSE diagnostic assays, where 
identification of PrPSc in post-mortem brain 
tissue indicates a TSE positive animal. 
However the relationship between PrPSc and 
TSE infectivity has not been definitively 
demonstrated, and concerns have been raised 
by earlier reports of disease transmission in 
the apparent absence of PrP-res (16,18). In 
particular, 101LL gene targeted transgenic 
mice inoculated with GSS P102L or 263K 
succumb to a disease which is highly 
transmissible to both 101LL and wild type 
mice, but shows extremely low levels of PrP-
res in the brain.  Extended analyses of this 
model (described here) have now used 
quantitative assays to unequivocally 
demonstrate that titres of 107 to 109 IU/g can 
be present in brain tissue which shows little or 
no abnormal PrP accumulation by standard 
immunoblot analysis, IHC, DELFIA or 
immunoprecipitation. These titres are similar 
to or higher than those observed in our well 
characterised, high titre control strain ME7, 
but for 4 of the 5 brains analysed, PrP-res 
levels were below the limit of detection of our 
immunoblot assay (<1.3% of the amount of 
PrP-res in wild type ME7 tissue).  Previous 
studies have shown that PrP-res from other 
well characterised rodent scrapie strains with 
titres ranging from 105.5 to 109 can be easily 
identified on immunoblot of 1% brain 
homogenate following PK treatment. Based 
on these previous data, it would be predicted 
that the tissues studied here should contain 
titres far below 105 IU/g tissue.  However the 
transmission data clearly show that 
101LL/GSS and 101LL/263K infected tissues 
contained high titres of infectivity which 
exceed those measured in both 79V and 22A 
infected tissue (Figure S1B).  These data 
suggest that current diagnostic assay systems 
which rely on PrPSc detection might fail to 
identify some highly infectious tissues. To this 
end, tissues from 101LL/GSS and 
101LL/263K infected mice are currently being 
assessed in several of these assay systems in 
our laboratory. 
 Several independent studies have 
previously shown that one TSE infectious unit 
is composed of approximately 105  PrP PSc 
molecules (2,14,15). In contrast to these 
studies the data obtained from 101LL/GSS 
and 101LL/263K infected tissues indicate that 
the number of PrPSc molecules per unit of 
infectivity must display a wide range, with 
101LL/GSS and 101LL/263K tissues showing 
between 10 to 1000 times fewer PrP-res 
molecules per unit infectivity than Wt/ME7.  
Alternatively, these data could indicate that 
only a very small proportion of PrPSc present 
in TSE infected tissue is actually infectious.  
This lack of correlation between levels of PrP-
res and infectivity do not support PrP-res as 
the infectious agent of TSE.   
 As PrP-res does not appear to be a major 
component of infectivity in this study, it is 
possible that another form of PrP is 
responsible for disease in these mice.  We 
have shown previously that 101LL mice can 
form PrP-res when inoculated with other 
rodent TSE strains (38), therefore the lack of 
PrPSc in these models is not due to an inherent 
inability of 101L-PrP to convert to a protease 
resistant isoform.  In contrast to the gene 
targeted transgenic 101LL mice described 
here, transgenic mice which overexpress 
101L-PrP at levels 8-16 fold higher than 
endogenous PrP develop a spontaneous 
neurological disease which appears to be 
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associated with a PK-sensitive form of PrPSc 
(21,22).  We have found no evidence of sPrPSc 
in 101LL/GSS or 101LL/263K brain tissue by 
either limited PK digestion studies or 
differential extraction in GdnHCl. 
Additionally, motif grafted MAbs which 
specifically bind PrPSc did not 
immunoprecipitate PK-sensitive forms of 
PrPSc, as had been observed in sick 101L 
overexpressing transgenic mice. One possible 
reason for this discrepancy between models is 
that disease in 101LL/GSS and 101LL/263K 
mice is due to a TSE infection which has been 
transmitted from a known infected source, and 
can be further passaged to both 101LL and 
wild type 129/Ola mice (18,19).  In contrast 
the disease observed in transgenic mice 
overexpressing 101L PrP does not transmit to 
wild type mice, and only appears to accelerate 
the phenotype already present in mice 
expressing lower levels of the transgene 
(17,22), suggesting that sPrPSc may instead be 
associated with overexpression of 101L-PrP 
and not TSE disease.  The species of abnormal 
PrP produced due to overexpression of 101L-
PrP is therefore different from that produced 
by TSE infection. The nature of the infectious 
agent in the current study has yet to be 
established.  We now aim to use this unique 
model to determine whether infectivity in 
these tissues is consistent with other abnormal 
conformations of PrP or with factors other 
than PrP.  
 The models of disease described here 
demonstrate the potential for the existence of 
high levels of TSE infectivity with 
undetectable PrP-res in natural disease.  
Indeed,  increased surveillance and sensitivity 
of testing methods has identified a new TSE 
of sheep, termed atypical scrapie. These 
animals were identified as TSE infected by 
one PrPSc specific diagnostic ELISA, but 
could not be confirmed by other methods 
(39,40). Such cases are now only identifiable 
using assays which require low concentrations 
of PK, or no PK in the assay procedure. It is 
unknown whether this is truly a new TSE of 
sheep, or whether it has been present in sheep 
for some time, but was not detected due to the 
reduced PK-resistance of PrPSc. However the 
disease has been shown to be highly 
transmissible to transgenic mice expressing 
ovine PrP (41) indicating the presence of 
substantial levels of infectivity. The results of 
our study raise concern over the suitability of 
PrPSc as a sole diagnostic marker of TSE 
disease. It is vital that markers of TSE 
infectivity other than PrPSc are identified and 
validated in models such as those we have 
described and characterised here.  We 
anticipate that such research will lead to the 
development of more robust diagnostic assays 
for TSE disease which will have important 
implications for both animal and human 
health.  
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FIGURE LEGENDS. 
 
Figure 1. Low levels of PrP deposition in 101LL/GSS and 101LL/263K infected brain.  
Immunohistochemistry was performed on sections of brain from 101LL/263K and 101LL/GSS 
infected mice using monoclonal antibody 6H4 to determine the levels of PrP deposition.  ME7 
infected control mouse brain was stained as control (F).  Five brains (3 x 101LL/263K and 2 x 
101LL/GSS) showing very low levels of deposition were selected for further analysis to quantify 
the levels of TSE infectivity and PrPSc in each tissue.  Very low levels of PrP deposition were 
observed in brain tissue, which varied between each individual mouse brain.  Deposition was 
mainly observed in the thalamus (Frames G-I). Frames A-F at x4 magnification, Frames G-I at 
x20 magnification. 
A: 101LL/263K(a).  B: 101LL/263K(b).  C: 101LL/263K(c).   D: 101LL/GSS(d).  E: 
101LL/GSS(e).  F: WT/ME7 control. G: thalamus of 101LL/263K(a).  H: thalamus of 
101LL/263K(c).  I: thalamus of 101LL/GSS(d) 
 
Figure 2. Low or undetectable levels of PrP-res in 101LL/GSS and 101LL/263K infected 
brain.  Residual inoculum from the tissues selected for ID50 bioassay were analysed by 
immunoblot following PK treatment to detect PrP-res.  Lanes 2 ,4, 6, 8, 10 and 12 digested with 
PK at 20µg/ml for 1h at 370C. Lanes 1, 3, 5, 7, 9 and 11 no PK control.  Lanes 1 and 2, uninfected 
Wt 129/Ola mouse;  Lanes 3 and 4, 101LL/263K(b);  Lanes 5 and 6, 101LL/263K(c);  Lanes 7 
and 8, 101LL/263K(a);  Lanes 9 and 10, 101LL/GSS(d);  Lanes 11 and 12, 101LL/GSS(e).  Blots 
probed with Mab 8H4.  
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Figure 3.  PK resistance of PrP in 101LL/GSS and 101LL/263K brain tissue. 
Brain homogenates in NP40 lysis buffer were digested with varying concentrations of proteinase 
K at 370C for 1h.  Samples were subjected to SDS PAGE and immunoblotting to determine the 
PK sensitivity of the PrP present in 101LL/GSS and 101LL/263K tissue.  Representative images 
showing; A, uninfected 101LL control mouse brain; B, uninfected Wt 129/Ola control mouse 
brain; C, 101LL/263K(a) mouse brain; D, 101LL/GSS (d) mouse brain; E, 101LL/263K(b) 
mouse brain.  PK concentration used for digestion shown above each lane (µg/ml).  Blots probed 
with MAbs 8H4 (B, C and E) or 7A12 (A and D). Bars indicate molecular weight markers of 
36kDa and 30kDa. 
 
Figure 4.  Cold PK Treatment of tissues from high titre/low PrP-res models. 
101LL/GSS and 101LL/263K tissues taken from the same transmission experiments as those 
shown in Table 1 were subjected to “Cold PK” digestion on ice.  Uninfected and Wt/ME7 
infected brains were also digested as controls.  Lane 1, undigested 101LL/GSS brain homogenate;  
Lane 2, 101LL/263K(g);  Lane 3, 101LL/GSS(f);  Lane 4, 101LL uninfected control;  Lane 5, Wt 
129/Ola uninfected control;  Lane 6, Wt/ME7 infected control.  Lanes 2-6 were treated with 
250µg/ml PK on ice for 1h and de-glycosylated with PNGase F.  ME7 control was loaded at 
approximately 25% of the concentration of lanes 2-5 to allow comparison. Blot probed with MAb 
7A12.  Image has been cropped from a single blot to remove lanes with samples which are not 
relevant to this figure. 
 
Figure 5.  DELFIA analysis of 101LL/GSS brain homogenate. 
Samples of 101LL/GSS brain homogenate, 101LL/263K homogenate and uninfected or ME7 
infected controls were analysed for presence of 1M GdnHCl insoluble PrP by DELFIA.  Light 
bars represent readings obtained from 1M GdnHCl soluble fractions, dark bars represent 1M 
GdnHCl insoluble fractions.  Sample 1, 101LL/GSS(d); Sample 2, 101LL/GSS; Sample 3, 
101LL/263K; Sample 4, uninfected 101LL Tg mouse; Sample 5, ME7 infected 129/Ola mouse.  
Sample 2 was a further tissue from the same experiment as 101LL/GSS(d) which showed no 
detectable PrP-res by immunoblot, but produced short incubation times on subpass to 101LL 
mice.  Due to the limitations of using a single mouse brain for each analysis, insufficient material 
was available to perform DELFIA analysis on 101LL/263K samples (a) to (c) described in Table 
1.  Sample 3 was a further 101LL/263K sample from the same experiment, which showed no PrP-
res by immunoblot. The hatched line indicates the level of PrP detected in the 1M GdnHCl 
insoluble fraction of uninfected 101LL tissue.  Capture antibody MAb FH11, detection antibody 
MAb 7A12.  Samples were assayed in duplicate, and the percentage coefficient of variance for 
each sample pair was ≤ 10. 
 
Figure 6. Immunoprecipitation using PrPSc-specific monoclonal antibodies. 
101LL/GSS and 101LL/263K tissues taken from the same transmission experiments as those 
shown in Table 1 were subjected to immunoprecipitation (IP) using PrPSc-specific MAbs 89-112 
and 136-158 to determine whether forms of PrPSc which were sensitive to PK were present in 
these tissues. MAb D13 which precipitates only cellular PrP, and MAb b12 which recognises the 
HIV gp120 antigen were used as IP controls. Panel A lanes 1-5, 101LL/GSS(h); Panel A lanes 6-
10, uninfected 101LL; Panel B lanes 1-5, 101LL/263K(i); Panel B lanes 6-10, uninfected 101LL; 
Panel C, RML scrapie WT control.  Lanes 1&6, crude brain homogenate. Lanes 2&7, IP with 
MAb D13 (positive control antibody). Lanes 3&8 IP with MAb b12 (negative control antibody).  
Lanes 4&9, IP with MAb 89-112. Lanes 5&10, IP with MAb 136-158. 
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Table 1.  Tissues selected for analysis. 
Details of clinical disease and vacuolar pathology in the 5 tissues selected for analysis.  All mice 
showed positive clinical and vacuolar signs of TSE disease and low levels of PrP deposition. 
 
Tissue used for 
titration. 
Clinical 
TSE 
Vacuolar 
Pathology 
PrP 
deposition* 
Incubation period (days ±SEM) 
   Primary†          Secondary‡
101LL/263K(a) positive positive + 385 109 ± 2 
101LL/263K(b) positive positive +/- 464 129 ± 2 
101LL/263K(c) positive positive +/- 534 262 ± 4 
101LL/GSS(d) positive positive + 259 154 ± 3 
101LL/GSS(e) positive positive +/- 252 123 ± 1 
* scoring of PrP deposition; +++ high, ++ medium, + low, +/- very small grainy deposits. 
†  Incubation time of each individual mouse on primary transmission of either 263K or P102L 
GSS. 
‡  Incubation time of 101LL mice inoculated with 1% brain homogenate from each specific 
101LL/263K or 101LL/GSS infected tissue. Transmission of disease on subpass to 101LL mice 
was 100% in each case. 
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Table 2. Comparison of Titre of infectivity and PrP-res level.   
PrP-res levels, quantified relative to recombinant PrP from digital immunoblot images, and 
infectivity titre, measured by  ID50 bioassay.  Detection limit of the immunoblot system was 
estimated to be equivalent to 25μg PrP-res /g wet weight brain.  
 
 
Model 
PrP-res 
(µg/g 
tissue)** 
PrP-res 
(% of 
ME7) 
Titre* 
(IU/g 
tissue) 
Wt/ME7 1994 100 108.5
101LL/ME7 1040 52 107.8
101LL/263K(a) 498 25 108.7
101LL/263K(b) < 25 < 1.3 107.3
101LL/263K(c) < 25 < 1.3 107.5
101LL/GSS(d) < 25 < 1.3 109.8
101LL/GSS(e) < 25 < 1.3 107.2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Titre of infectivity per gram of brain tissue as calculated from ID50 bioassay in mice using the 
Karber calculation. 
**The actual amount of PrP-res quantified from the blots (0.5-2mg/g) is higher than would be 
predicted for mouse tissue, and may reflect the use of recombinant PrP for calibration, as this 
does not possess any post-translational modifications, and may therefore display altered antibody 
affinity.  However this internal control acts to normalise each blot, and therefore ensures that the 
relative proportions of PrP-res between each model are real, despite possible errors in the absolute 
quantification.  
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